An emphasis on molecular mechanisms of anti-inflammatory effects and glucocorticoid resistance

Journal of Complementary and Integrative Medicine

Volumn 12, Issue 1, 2015, Pages 1-13

  Ingawale, Deepa K ^a,b   Mandlik, Satish K ^c   Patel, Snehal S ^d  

^a Sinhgad Institute of Pharmaceutical Sciences   (India)

^b NIRMA UNIVERSITY   (India)

^c SINHGAD COLLEGE OF PHARMACY   (India)

^d NONE

Author keywords

Cytokines; Glucocorticoid resistance; Glucocorticoids; Inflammation; Interleukins

Indexed keywords

ALLERGEN; ALPHA TOCOPHEROL; ANTIINFLAMMATORY AGENT; AZATHIOPRINE; CALCINEURIN INHIBITOR; CHEMOKINE RECEPTOR ANTAGONIST; CIGARETTE SMOKE; COLLAGEN; CYTOKINE; DEXAMETHASONE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; HISTONE; HISTONE DEACETYLASE 2; I KAPPA B KINASE ALPHA; IMMUNOMODULATING AGENT; INTERLEUKIN 10; LIPOCORTIN 1; MACROPHAGE MIGRATION INHIBITION FACTOR; MERCAPTOPURINE; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; MULTIDRUG RESISTANCE PROTEIN; PHOSPHODIESTERASE IV INHIBITOR; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; THEOPHYLLINE; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA1; UNINDEXED DRUG; VITAMIN D;

ADAPTIVE IMMUNITY; ALLERGIC ASTHMA; ANTIINFLAMMATORY ACTIVITY; ASTHMA; CELL MEMBRANE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYTOKINE PRODUCTION; DISEASE SEVERITY; DRUG EFFICACY; GENE EXPRESSION; GENE REPRESSION; GENE TRANSLOCATION; GENETIC SUSCEPTIBILITY; HISTONE ACETYLATION; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; HYPOXIA; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; INFLAMMATORY DISEASE; INNATE IMMUNITY; LEUKOCYTE; LIGAND BINDING; NEUTROPHILIA; NONHUMAN; OXIDATIVE STRESS; PERIPHERAL BLOOD MONONUCLEAR CELL; PHAGOCYTE; PROTEIN PHOSPHORYLATION; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SIGNAL TRANSDUCTION; TRANSACTIVATION; TRANSCRIPTION INITIATION; TUMOR MICROENVIRONMENT; VIRUS INFECTION; ANIMAL; DRUG RESISTANCE; METABOLISM;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CYTOKINES; DRUG RESISTANCE; GLUCOCORTICOIDS; HUMANS; INFLAMMATION; RECEPTORS, GLUCOCORTICOID; SIGNAL TRANSDUCTION;

EID: 84922658215     PISSN: None     EISSN: 15533840     Source Type: Journal    
DOI: 10.1515/jcim-2014-0051     Document Type: Review

References (109)

1. Beato M, Klug J. Steroid hormone receptors: an update. Hum Reprod Update 2000;6:225-36.
2. Barnes PJ. Corticosteroids: the drugs To Beat. Eur J Pharmacol 2006;533:2-14.
3. Newton R, Leigh R, Giembycz MA. Pharmacological strategies for improving the efficacy and therapeutic ratio of glucocorticoids in inflammatory lung diseases. Pharmacol Ther 2010;125:286-327.
4. Barnes PJ. Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease. J Allergy Clin Immunol 2013;131:636-45.
5. McDonough AK, Curtis JR, Saag KG. The epidemiology of glucocorticoid- associated adverse events. Curr Opin Rheumatol 2008;20:131-7.
6. Stahn C, Buttgereit F. Genomic and nongenomic effects of glucocorticoids. Nat Clin Pract Rheumatol 2008;4:525-33.
7. Kleiman A, Tuckermann JP. Glucocorticoid receptor action in beneficial and side effects of steroid therapy: lessons from conditional knockout mice. Mol Cell Endocrinol 2007;275:98-108.
8. Perretti M, Ahluwalia A. The microcirculation and inflammation: site of action for glucocorticoids. Microcirculation 2000;7:147-61.
9. McEwen BS, Biron CA, Brunson KW, Bulloch K, Chambers WH, Dhabhar FS, et al. The role of adrenocorticoids as modulators of immune function in health and disease: neural, endocrine and immune interactions. Brain Res Rev 1997;23:79-133.
10. Herold MJ, McPherson KG, Reichardt HM. Glucocorticoids in T cell apoptosis and function. Cell Mol Life Sci 2006;63:60-72.
11. McColl A, Michlewska S, Dransfield I, Rossi AG. Effects of glucocorticoids on apoptosis and clearance of apoptotic cells. Sci World J 2007;7:1165-81.
12. Smoak KA, Cidlowski JA. Mechanisms of glucocorticoid receptor signaling during inflammation. Mech Ageing Dev 2004;125:697-706.
13. Nissen RM, Yamamoto KR. The glucocorticoid receptor inhibits NFκB by interfering with serine-2 phosphorylation of the RNA polymerase II carboxy-terminal domain. Genes Dev 2000;14:2321-9.
14. Buttgereit F, Burmester GR. Glucocorticoids. In: John HK, John HS, Leslie JC, Patience HW. Primer on the rheumatic diseases. Springer, 13th ed. 2008:644-50.
15. Hafezi-Moghadam A, Simoncini T, Yang Z, Limbourg FP, Plumier JC, Rebsamen MC, et al. Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase. Nat Med 2002;8:473-9.
16. Solito E, Mulla A, Morris JF, Christian HC, Flower RJ, Buckingham JC, et al. Dexamethasone induces rapid serine-phosphorylation and membrane translocation of annexin 1 in a human folliculostellate cell line via a novel nongenomic mechanism involving the glucocorticoid receptor, protein kinase C, phosphatidylinositol 3-kinase, and mitogen-activated protein kinase. Endocrinology 2003;144:1164-74.
17. Watson CS, Gametchu B. Membrane-initiated steroid actions and the proteins that mediate them. Proc Soc Exp Biol Med 1999;220:9-19.
18. Perretti M, D'Acquisto F. Annexin A1 and glucocorticoids as effectors of the resolution of inflammation. Nat Rev Immunol 2009;9:62-70.
19. Meijsing SH, Pufall MA, So AY, Bates DL, Chen L, Yamamoto KR. DNA binding site sequence directs glucocorticoid receptor structure and activity. Science 2009;324:407-10.
20. Lonard DM, O'Malley BW. Nuclear receptor coregulators: judges, juries, and executioners of cellular regulation. Mol Cell 2007;27:691-700.
21. Barnes PJ. Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci (Lond 1998;94:557-72.
22. Beaulieu E, Morand EF. Role of GILZ in immune regulation, glucocorticoid actions and rheumatoid arthritis. Nat Rev Rheumatol 2011;7:340-8.
23. Ayroldi E, Riccardi C. Glucocorticoid-induced leucine zipper (GILZ): a new important mediator of glucocorticoid action. FASEB J 2009;23:3649-58.
24. He SH, Chen P, Chen HQ. Modulation of enzymatic activity of human mast cell tryptase and chymase by protease inhibitors. Acta Pharm Sin 2003;24:923-9.
25. Solito E, de Coupade C, Parente L, Flower RJ, Russo-Marie F. IL-6 stimulates annexin 1 expression and translocation and suggests a new biological role as class II acute phase protein. Cytokine 1998;10:514-21.
26. Croxtall JD, Choudhury Q, Tokumoto H, Flower RJ. Lipocortin-1 and the control of arachidonic acid release in cell signalling. Glucocorticoids (changed from glucorticoids) inhibit G protein dependent activation of cPLA2 activity. Biochem Pharmacol 1995;50:465-74.
27. Grutz G. New insights into the molecular mechanism of inter-leukin-10-mediated immunosuppression. J Leukoc Biol 2005;77:3-15.
28. Roffe E, Rothfuchs AG, Santiago HC, Marino AP, Ribeiro-Gomes FL, Eckhaus M, et al. IL-10 limits parasite burden and protects against fatal myocarditis in a mouse model of trypanosoma cruzi infection. J Immunol 2012;188:649-60.
29. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M. Immunosuppression by glucocorticoids: inhibition of NF-kappa-B activity through induction of I-kappa-B synthesis. Science 1995;270:286-90.
30. Adcock IM. Molecular mechanisms of glucocorticosteroids actions. Pulm Pharmacol Ther 2000;13:115-26.
31. Karin M. New twists in gene regulation by glucocorticoid receptor: is DNA binding dispensable?. Cell 1998;93:487-90.
32. Rosenfeld MG, Glass CK. Coregulator codes of transcriptional regulation by nuclear receptors. J Biol Chem 2001;276:36865-8.
33. Pascual G, Fong AL, Ogawa S, Gamliel A, Li AC, Perissi V, et al. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature 2005;437:759-63.
34. Luecke HF, Yamamoto KR. The glucocorticoid receptor blocks P-TEFb recruitment by NFkappaB to effect promoter-specific transcriptional repression. Genes Dev 2005;19:1116-27.
35. Barnes PJ, Adcock IM. Glucocorticoid resistance in inflammatory diseases. Lancet 2009;373:1905-1917.
36. Hew M, Chung KF. Corticosteroid insensitivity in severe asthma: significance, mechanisms and aetiology. Intern Med J 2010;40:323-34.
37. Chaudhuri R, Livingston E, McMahon AD, Thomson L, Borland W, Thomson NC. Cigarette smoking impairs the therapeutic response to oral corticosteroids in chronic asthma. Am J Respir Crit Care Med 2003;168:1308-11.
38. Okamoto K, Tanaka H, Ogawa H, Makino Y, Eguchi H, Hayashi S, et al. Redox-dependent regulation of nuclear import of the glucocorticoid receptor. J Biol Chem 1999;274:10363-71.
39. Ito K, Hanazawa T, Tomita K, Barnes PJ, Adcock IM. Oxidative stress reduces histone deacetylase 2 activity and enhances IL-8 gene expression: role of tyrosine nitration. Biochem Biophys Res Commun 2004;315:240-5.
40. Hawrylowicz C, Richards D, Loke TK, Corrigan C, Lee T. A defect in corticosteroid-induced IL-10 production in T lymphocytes from corticosteroid- resistant asthmatic patients. J Allergy Clin Immunol 2002;109:369-70.
41. Xystrakis E, Kusumakar S, Boswell S, Peek E, Urry Z, Richards DF, et al. Reversing the defective induction of IL-10-secreting regulatory T cells in glucocorticoid-resistant asthma patients. J Clin Invest 2006;116:146-55.
42. Johnston SL. Overview of virus-induced airway disease. Proc Am Thorac Soc 2005;2:150-6.
43. Bellattato C, Adcock IM, Ito K, Caramori G, Casolari P, Ciaccia A, et al. Rhinovirus infection reduces glucocorticoid receptor nuclear translocation in airway epithelial cells. Eur Respir J 2003;22:565S.
44. Wenzel SE, Szefler SJ, Leung DY, Sloan SI, Rex MD, Martin RJ. Bronchoscopic evaluation of severe asthma. Persistent inflammation associated with high dose glucocorticoids. Am J Respir Crit Care Med 1997;156:737-43.
45. Camps M, Ruckle T, Ji H, Ardissone V, Rintelen F, Shaw J, et al. Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat Med 2005;11:936-43.
46. Zhang X, Moilanen E, Adcock IM, Lindsay MA, Kankaanranta H. Divergent effect of mometasone on human eosinophil and neutrophil apoptosis. Life Sci 2002;71:1523-34.
47. Leung DY, Bloom JW. Update on glucocorticoid action and resistance. J Allergy Clin Immunol 2003;111:3-22.
48. Nimmagadda SR, Szefler SJ, Spahn JD, Surs W, Leung DY. Allergen exposure decreases glucocorticoid receptor binding affinity and steroid responsiveness in atopic asthmatics. Am J Respir Crit Care Med 1997;155:87-93.
49. De Iudicibus S, Franca R, Martelossi S, Ventura A, Decorti G. Molecular mechanism of glucocorticoid resistance in inflammatory bowel disease. World J Gastroenterol 2011;17:1095-108.
50. Barnes PJ, Ito K, Adcock IM. Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase. Lancet 2004;363:731-3.
51. Hew M, Bhavsar P, Torrego A, Meah S, Khorasani N, Barnes PJ, et al. Relative corticosteroid insensitivity of peripheral blood mononuclear cells in severe asthma. Am J Respir Crit Care Med 2006;174:134-41.
52. To Y, Ito K, Kizawa Y, Failla M, Ito M, Kusama T, et al. Targeting phosphoinositide-3-kinase-delta with theophylline reverses corticosteroid insensitivity in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010;182:897-904.
53. Karhausen J, Haase VH, Colgan SP. Inflammatory hypoxia: role of hypoxiainducible factor. Cell Cycle 2005;4:256-8.
54. Murata T, Hori M, Sakamoto K, Karaki H, Ozaki H. Dexamethasone blocks hypoxia-induced endothelial dysfunction in organ-cultured pulmonary arteries. Am J Respir Crit Care Med 2004;170:647-55.
55. Kodama T, Shimizu N, Yoshikawa N, Makino Y, Ouchida R, Okamoto K, et al. Role of the glucocorticoid receptor for regulation of hypoxia-dependent gene expression. J Biol Chem 2003;278:33384-91.
56. Wagner AE, Huck G, Stiehl DP, Jelkmann W, Hellwig-Burgel T. Dexamethasone impairs hypoxia-inducible factor-1 function. Biochem Biophys Res Commun 2008;372:336-40.
57. Leung DY, Martin RJ, Szefler SJ, Sher ER, Ying S, Kay AB, et al. Dysregulation of interleukin 4, interleukin 5, and interferon gamma gene expression in steroid-resistant asthma. J Exp Med 1995;18:33-40.
58. Matthews JG, Ito K, Barnes PJ, Adcock IM. Defective glucocorticoid receptor nuclear translocation and altered histone acetylation patterns in glucocorticoid-resistant patients. J Allergy Clin Immunol 2004;113:1100-8.
59. Irusen E, Matthews JG, Takahashi A, Barnes PJ, Chung KF, Adcock IM. P38 mitogen-activated protein kinase-induced glucocorticoid receptor phosphorylation reduces its activity: role in steroid-insensitive asthma. J Allergy Clin Immunol 2002;109:649-57.
60. Ishiguro Y. Mucosal proinflammatory cytokine production correlates with endoscopic activity of ulcerative colitis. J Gastroenterol 1999;34:66-74.
61. Roger T, Chanson AL, Knaup-Reymond M, Calandra T. Macrophage migration inhibitory factor promotes innate immune responses by suppressing glucocorticoid-induced expression of mitogen-activated protein kinase phosphatase-1. Eur J Immunol 2005;35:3405-13.
62. Carmichael J, Paterson IC, Diaz P, Crompton GK, Kay AB, Grant IB. Corticosteroid resistance in asthma. BMJ 1981;282:1419-22.
63. Hakonarson H, Bjornsdottir US, Halapi E, Bradfield J, Zink F, Mouy M, et al. Profiling of genes expressed in peripheral blood mononuclear cells predicts glucocorticoid sensitivity in asthma patients. Proc Natl Acad Sci USA 2005;102:14789-94.
64. Salem S, Harris T, Mok JSL, Li MYS, Keenan CR, Schuliga MJ, et al. Transforming growth factor-b impairs glucocorticoid activity in the A549 lung adenocarcinoma cell line. Br J Pharmacol 2012;166:2036-48.
65. Franchimont D, Martens H, Hagelstein MT, Louis E, Dewe W, Chrousos GP, et al. Tumor necrosis factors alpha decreases, and interleukin-10 increases, the sensitivity of human monocytes to dexamethasone: potential regulation of the glucocorticoid receptor. J Clin Endocrinol Metab 1999;84:2834-9.
66. Sousa AR, Lane SJ, Cidlowski JA, Staynov DZ, Lee TH. Glucocorticoid resistance in asthma is associated with elevated in vivo expression of the glucocorticoid receptor beta-isoform. J Allergy Clin Immunol 2000;105:943-50.
67. Kozaci DL, Chernajovsky Y, Chikanza IC. The differential expression of corticosteroid receptor isoforms in corticoster-oid-resistant and -sensitive patients with rheumatoid arthritis. Rheumatol 2007;46:579-85.
68. Orii F, Ashida T, Nomura M, Maemoto A, Fujiki T, Ayabe T, et al. Quantitative analysis for human glucocorticoid receptor alpha/beta mRNA in IBD. Biochem Biophys Res Commun 2002;296:1286-94.
69. Fakhri S, Tulic M, Christodoulopoulos P, Fukakusa M, Frenkiel S, Leung DY, et al. Microbial superantigens induce glucocorticoid receptor beta and steroid resistance in a nasal explant model. Laryngoscope 2004;114:887-92.
70. Ito K, Barnes PJ, Adcock IM. Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits IL-1β-induced histone H4 acetylation on lysines 8 and 12. Mol Cell Biol 2000;20:6891-903.
71. Redington AE. Fibrosis and airway remodelling. Clin Exp Allergy 2000;30:42-5.
72. Ebina M, Takahashi T, Chiba T, Motomiya M. Cellular hypertrophy and hyperplasia of airway smooth muscles underlying bronchial asthma: a 3-D morphometric study. Am Rev Respir Dis 1993;148:720-6.
73. Bonacci JV, Schuliga M, Harris T, Stewart AG. Collagen impairs glucocorticoid actions in airway smooth muscle through integrin signalling. Br J Pharmacol 2006;149:365-73.
74. Li Z, Jiao X, Wang C, Ju X, Lu Y, Yuan L, et al. Cyclin D1 induction of cellular migration requires p27(KIP1). Cancer Res 2006;66:9986-94.
75. Loke TK, Mallett KH, Ratoff J, O'Connor BJ, Ying S, Meng Q, et al. Systemic glucocorticoid reduces bronchial mucosal activation of activator protein 1 components in glucocorticoid-sensitive but not glucocorticoid-resistant asthmatic patients. J Allergy Clin Immunol 2006;118:368-75.
76. Lane SJ, Adcock IM, Richards D, Hawrylowicz C, Barnes PJ, Lee TH. Corticosteroid-resistant bronchial asthma is associated with increased c-fos expression in monocytes and T-lymphocytes. J Clin Invest 1998;102:2156-64.
77. Flaster H, Bernhagen J, Calandra T, Bucala R. The macrophage migration inhibitory factor-glucocorticoid dyad: regulation of inflammation and immunity. Mol Endocrinol 2007;21:1267-80.
78. Ishiguro Y, Ohkawara T, Sakuraba H, Yamagata K, Hiraga H, Yamaguchi S, et al. Macrophage migration inhibitory factor has a proinflammatory activity via the p38 pathway in glucocorticoid-resistant ulcerative colitis. Clin Immunol 2006;120:335-41.
79. Farrell RJ, Murphy A, Long A, Donnelly S, Cherikuri A, O'Toole D, et al. High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy. Gastroenterol 2000;118:279-88.
80. Farrell RJ, Kelleher D. Glucocorticoid resistance in inflammatory bowel disease. J Endocrinol 2003;178:339-46.
81. Tsujimura S, Saito K, Nawata M, Nakayamada S, Tanaka Y. Overcoming drug resistance induced by P-glycoprotein on lymphocytes in patients with refractory rheumatoid arthritis. Ann Rheum Dis 2008;67:380-8.
82. Hawrylowicz CM. Regulatory T cells and IL-10 in allergic inflammation. J Exp Med 2005;202:1459-63.
83. Stanczyk J, Ospelt C, Gay S. Is there a future for small molecule drugs in the treatment of rheumatic diseases?. Curr Opin Rheumatol 2008;20:257-62.
84. Cosio BG, Tsaprouni L, Ito K, Jazrawi E, Adcock IM, Barnes PJ. Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. J Exp Med 2004;200:689-95.
85. Fox JC, Spicer D, Ito K, Barnes PJ, Fitzgerald MF. Oral or inhaled corticosteroid combination therapy with low dose theophylline reverses corticosteroid insensitivity in a smoking mouse model. Proc Am Thorac Soc 2007;2:A637.
86. Failla M, To Y, Ito M, Adcock IM, Barnes PJ, Ito K. Oxidative stress-induced PI3-kinase activation reduces HDAC activity and is inhibited by theophylline. Proc Am Thorac Soc 2007;2:A45.
87. Rahman I, Adcock IM. Oxidative stress and redox regulation of lung inflammation in COPD. Eur Respir J 2006;28:219-42.
88. Nobili S, Landini I, Giglioni B, Mini E. Pharmacological strategies for overcoming multidrug resistance. Curr Drug Targets 2006;7:861-79.
89. Huschtscha L, Bartier W, Ross C, Tattersall M. Characteristics of cancer cell death after exposure to cytotoxic drugs in vitro. Br J Cancer 1996;73:54-60.
90. Feagan BG, Rochon J, Fedorak RN, Irvine EJ, Wild G, Sutherland L, et al. The North American Crohn's study group. Methotrexate for the treatment of Crohn's disease. N Engl J Med 1995;332:292-7.
91. Stack W, Williams D, Stevenson M, Logan R. Immunosuppressive therapy for ulcerative colitis: results of a nation-wide survey among consultant physician members of the British society of gastroenterology. Aliment Pharmacol Ther 1999;13:569-75.
92. Jewell D, Truelove S. Azathioprine in ulcerative colitis: final report on controlled therapeutic trial. BMJ 1974;114:627-30.
93. Gordon F, Lai C, Hamilton M, Allison M, Srivastava E, Fouweather M, et al. A randomized placebo-controlled trial of a humanized monoclonal antibody to α4 integrin in active Crohn's disease. Gastroenterology 2001;121:268-174.
94. Van Assche G, Dalle I, Noman M, Aerden I, Swijsen C, Asnong K, et al. A pilot study on the use of the humanized anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitis. Am J Gastroenterol 2003;98:369-76.
95. Kitahara K, Kawai S. Cyclosporine and tacrolimus for the treatment of rheumatoid arthritis. Curr Opin Rheumatol 2007;19:238-45.
96. Dastidar SG, Rajagopal D, Ray A. Therapeutic benefit of PDE4 inhibitors in inflammatory diseases. Curr Opin Investig Drugs 2007;8:364-72.
97. Stadtmann A, Zarbock A. CXCR2: from bench to bedside. Front Immunol 2012;3:263.
98. Chung KF. P38 mitogen-activated protein kinase pathways in asthma and COPD. Chest 2011;139:1470-9.
99. Fung-Leung WP. Phosphoinositide 3-kinase delta (PI3Kdelta) in leukocyte signaling and function. Cell Signal 2011;23:603-8.
100. Marwick JA, Caramori G, Casolari P, Mazzoni F, Kirkham PA, Adcock IM, et al. A role for phosphoinositol 3- kinase delta in the impairment of glucocorticoid responsiveness in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol 2010;125:1146-53.
101. Brusselle GG, Joos GF, Bracke KR. New insights into the immunology of chronic obstructive pulmonary disease. Lancet 2011;378:1015-26.
102. Pace E, Ferraro M, Siena L, Melis M, Montalbano AM, Johnson M, et al. Cigarette smoke increases toll-like receptor 4 and modifies lipopolysaccharide-mediated responses in airway epithelial cells. Immunol 2008;124:401-11.
103. Basith S, Manavalan B, Lee G, Kim SG, Choi S. Toll-like receptor modulators: a patent review (2006-2010). Expert Opin Ther Pat 2011;21:927-44.
104. Kwak JH, Jung JK, Lee H. Nuclear factor-kappa B inhibitors; a patent review (2006-2010). Expert Opin Ther Pat 2011;21:1897-910.
105. Bakke PS, Zhu G, Gulsvik A, Kong X, Agusti AG, Calverley PM, et al. Candidate genes for COPD in two large data sets. Eur Respir J 2011;37:255-63.
106. Barnes PJ. Scientific rationale for combination inhalers with a long-acting b2-agonists and corticosteroids. Eur Respir J 2002;19:182-91.
107. Usmani OS, Ito K, Maneechotesuwan K, Ito M, Johnson M, Barnes PJ, et al. Glucocorticoid receptor nuclear translocation in airway cells following inhaled combination therapy. Am J Respir Crit Care Med 2005;172:704-12.
108. Giembycz MA, Kaur M, Leigh R, Newton RA. Holy grail of asthma management: toward understanding how long-acting beta(2)-adrenoceptor agonists enhance the clinical efficacy of inhaled corticosteroids. Br J Pharmacol 2008;153:1090-104.
109. Kobayashi Y, Mercado N, Miller-Larsson A, Barnes PJ, Ito K. Increased corticosteroid sensitivity by a long acting beta2 agonist formoterol via beta2 adrenoceptor independent protein phosphatase 2a activation. Pulm Pharmacol Ther 2012;25:201-7.